Related Experiment Video
Updated: Jan 13, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Lenacapavir - a strong weapon to accelerate HIV prevention
1Instituto de Saúde Ambiental; Faculdade de Medicina da Universidade de Lisboa. Lisbon, Portugal.
Abstract:
Globally, the 2025 prevention target, that is, 95% of people at risk of HIV infection having access to and using effective combination prevention options, is not within reach. Rapid, wider access to pre-exposure prophylaxis (PrEP) could quickly reduce the number of new infections, ultimately among people from key populations. In 2015, the World Health Organization recommended daily oral PrEP using tenofovir-based drugs; however, expanded access to PrEP is still limited. Key barriers to HIV PrEP uptake and persistence are daily adherence, fear of stigma and discrimination, and limited awareness of the acceptability of and access to PrEP services. Long-acting options could address these barriers. New prevention products such as long-acting injectable cabotegravir and, most recently, lenacapavir provide very high levels of protection against HIV when compared with daily oral PrEP.
Related Concept Videos
Retrovirus Life Cycles
Retroviruses
Subviral Agents
Pharmacokinetics: Drug–Food and Drug–Viral Interactions

